Soligenix Management

Management Kriterienprüfungen 4/4

Soligenix's CEO ist Christopher Schaber , ernannt in Aug 2006, hat eine Amtszeit von 17.83 Jahren. Die jährliche Gesamtvergütung beträgt $700.49K , bestehend aus 74.2% Gehalt und 25.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.038% der Aktien des Unternehmens, im Wert von $1.59K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 10 Jahre bzw. 15 Jahre.

Wichtige Informationen

Christopher Schaber

Geschäftsführender

US$700.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	74.2%
Amtszeit als Geschäftsführer	17.8yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	10yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	15yrs

Jüngste Management Updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Christopher Schaber im Vergleich zu den Einnahmen von Soligenix verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

Vergütung im Vergleich zum Markt: ChristopherDie Gesamtvergütung ($USD700.49K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD678.50K).

Entschädigung vs. Einkommen: ChristopherDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Christopher Schaber (58 yo)

17.8yrs

Amtszeit

US$700,485

Vergütung

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	17.8yrs	US$700.49k	0.038% $ 1.0k
Jonathan Guarino	Senior VP	4.8yrs	US$354.69k	0.0047% $ 125.6
Oreola Donini	Senior VP & Chief Scientific Officer	9.5yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.4yrs	US$249.94k	0.0033% $ 90.0

10.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: SNGXDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (10 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	17.8yrs	US$700.49k	0.038% $ 1.0k
Jerome Zeldis	Independent Director	13yrs	US$72.50k	0.0097% $ 262.0
Gregory Lapointe	Independent Director	15.3yrs	US$77.50k	0.0031% $ 84.6
Robert Rubin	Independent Director	14.7yrs	US$80.00k	0.0018% $ 49.1
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten

15.0yrs

Durchschnittliche Betriebszugehörigkeit

69.5yo

Durchschnittliches Alter

Erfahrener Vorstand: SNGXDie Vorstandsmitglieder sind sehr erfahren ( 15 ).

Soligenix Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Recent updates

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

Price target decreased to US$3.88

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)